The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IVVD | +77.14% | N/A | N/A | -91% |
| S&P | +14.5% | +93.32% | +14.09% | +51% |
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.79M | 420.6% |
| Gross Profit | $10.60M | 537.7% |
| Gross Margin | 89.92% | 16.5% |
| Market Cap | $85.77M | -34.6% |
| Market Cap / Employee | $0.87M | 0.0% |
| Employees | 99 | 5.3% |
| Net Income | -$14.66M | 69.0% |
| EBITDA | -$14.56M | 70.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $34.91M | -76.4% |
| Accounts Receivable | $8.70M | 201.2% |
| Inventory | 0.4 | -91.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.90M | 0.0% |
| Short Term Debt | $1.07M | 56.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -82.65% | 0.1% |
| Return On Invested Capital | -106.74% | -36.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13.31M | 68.0% |
| Operating Free Cash Flow | -$13.30M | 68.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.87 | 0.64 | 1.07 | 1.58 | 115.60% |
| Price to Sales | 10.54 | 2.09 | 1.98 | 1.86 | -96.80% |
| Price to Tangible Book Value | 0.87 | 0.64 | 1.07 | 1.58 | 115.60% |
| Enterprise Value to EBITDA | -0.27 | 0.84 | -1.57 | -3.70 | -1234.18% |
| Return on Equity | -136.6% | -138.7% | -122.7% | -120.1% | 24.36% |
| Total Debt | $1.63M | $1.30M | $0.89M | $2.97M | 335.39% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
